A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
The primary objectives are to identify the highest safe and well-tolerated dose and frequency of BIIB017 (PEGylated Interferon Beta-1a) subcutaneous (SC), within the range of 63 to 188 mcg, when given every other week or every 4 weeks to healthy volunteers (HV).
Key facts
- Study ID
- NCT02125578
- Run by
- Biogen
- People needed
- 69
- Starts
- 2008-03-01
- Expected to finish
- 2008-05-01
- Last updated by the study team
- 2014-04-29
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.